532834 logo

Camlin Fine Sciences Limited Stock Price

BSE:532834 Community·₹19.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

532834 Share Price Performance

₹0
-202.35 (-100.00%)
₹177.50
Fair Value
₹0
-202.35 (-100.00%)
Price ₹0

532834 Community Narratives

·
Fair Value ₹177.5 42.1% undervalued intrinsic discount

Tariff Benefits And Safety Trends Will Boost US And Europe

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value ₹140 26.6% undervalued intrinsic discount

Tariffs And Chinese Pricing Will Pressure Antioxidant Demand Yet Leave Long Term Potential Intact

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value ₹190 45.9% undervalued intrinsic discount

Vanillin Expansion And Blends Demand Will Transform Earnings Power Over The Coming Years

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

532834 logo

532834: Higher Profitability Assumptions And New Global CFO Role Will Drive Upside

Fair Value: ₹140 26.6% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
532834 logo

532834: Future Margin Assumptions Will Support Bullish Re Rating Potential

Fair Value: ₹190 45.9% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
532834 logo

532834: Capital Structure Changes Will Support Bullish Outlook Despite CFO Role Shift

Fair Value: ₹177.5 42.1% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential.

2 Risks
3 Rewards

Camlin Fine Sciences Limited Key Details

₹18.4b

Revenue

₹10.4b

Cost of Revenue

₹8.0b

Gross Profit

₹8.5b

Other Expenses

-₹548.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-2.86
43.58%
-2.99%
72.0%
View Full Analysis

About 532834

Founded
1931
Employees
674
CEO
Ashish Dandekar
WebsiteView website
www.camlinfs.com

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally. The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), tert butylcatechol (TBC), Guaiacol, and Veratrole; and health and wellness products comprising algae based products, such as Omega 3 fatty acids. It sells its products under the Xtendra, Nasure, Ezential, adorr, Vitafor, Dinamic, and Biosus brands. The company’s products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries. The company was formerly known as Camlin Fine Chemicals Ltd. and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.

Recent 532834 News & Updates

Narrative Update Aug 17

532834: Higher Profitability Assumptions And New Global CFO Role Will Drive Upside

Analysts have trimmed their price target on Camlin Fine Sciences from ₹165.0 to ₹140.0, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What’s in the News for Camlin Fine Sciences Board meeting scheduled on May 26, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to finalize details for the 33rd Annual General Meeting.

Recent updates

No updates